… of the target protein. The broad applicability of this … protein degradation. We then offer a
comprehensive account of the most promising degraders in development as cancer therapies to …

… of protein degradation in Escherichia coli, where we discovered a new type of enzyme – large
multisubunit proteolytic complexes that cleave proteins … specificity for protein degradation. …

… proteolytic degradation includes a large variety of proteins … implausible therapeutic target for
a highly selective cancer therapy… the therapeutic potential of such agents, not only in cancer …

… Proteolysis targeting chimeric (PROTAC) technology is an effective endogenous protein
degradation tool developed in recent years that can ubiquitinate the target proteins through the …

… It is concluded that concomitant inhibition of the two main cellular protein degradation
systems may provide new therapeutic modalities for cancer treatment. (Folia Histochemica …

… To date, PROTACs targeting ~ 50 proteins, many of which are clinically validated … cancer
therapy. This article reviews PROTAC-mediated degradation of critical oncoproteins in cancer, …

… including resiliency to acquired mutations in the target protein, … proteins. Herein, we review
the development of proteolysis targeting chimeras (PROTACs) for selected cancer therapy …

… ; induction of targeted protein degradation of disease-relevant proteins is the dominant …
polypharmacology of multiple degraded neosubstrate proteins. Cancers acquire resistance …

… proteins. Currently, substantial efforts have been employed to develop new strategies for
inducing protein degradation. … has emerged as a novel therapeutic method to address diseases …

… Abstract: Drug discovery in the scope of cancer therapy has been focused on conventional …
without affecting their protein levels. An emerging therapeutic strategy that garnered attention …